A new therapy that ”helps very ill coronavirus patients recover in 72 hours.” has been discovered by scientists. According to researchers, there is evidence that blood plasma taken from patients who recovered and transmitted to seriously ill coronavirus patients is highly effective.
They said permission has now been given to University Hospital Erlangen, Germany, to produce therapeutic plasma to treat critically ill Covid-19 patients.
Also, some doctors in China treated critically ill patients in separate hospitals with antibody-rich plasma from recovered patients and recorded striking improvements in many of them within three days.
In one pilot study, doctors in Wuhan, China, gave “convalescent plasma” to 10 severely ill patients and found that virus levels in their bodies dropped rapidly. Within three days, the doctors saw improvements in the patient’s symptoms, ranging from shortness of breath and chest pains to fever and coughs.
The therapy known as Convalescent plasma treatment dates back to the 1918 Spanish flu pandemic. The therapy relies on the fact that people who have recovered from a viral infection have antibodies in their blood that can rapidly detect and destroy the virus the next time it attacks.
Professor David Tappin, a senior research fellow at the University of Glasgow, has applied to the UK’s National Institute for Health Research to run two clinical trials with convalescent plasma.
“The outcomes are also encouraging for these patients,” he said. But he added that to be sure plasma improved the natural course of the disease and that it was safe in larger groups of patients, formal trials had to take place. The treatment should be carefully examined by Professor Munir Pirmohamed, the president of the British Pharmacological Society.
“This was not a randomized trial and all patients also received other treatments, including antivirals such as remdesivir, which are currently in trials for COVID-19,” he said.
“It is also important to remember that there are potential safety concerns with convalescent plasma, including the transmission of other agents and antibody enhancement of disease,” he added. “Even if shown to work, scalability to treat large numbers of patients may become an issue.”